Editas Free Cash Flow Yield vs Ev To Free Cash Flow Analysis

EDIT Stock

USD 1.27 0.07 5.83%

Editas Medicine financial indicator trend analysis is much more than just examining Editas Medicine latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Editas Medicine is a good investment. Please check the relationship between Editas Medicine Free Cash Flow Yield and its Ev To Free Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Free Cash Flow Yield vs Ev To Free Cash Flow

Free Cash Flow Yield vs Ev To Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Editas Medicine Free Cash Flow Yield account and Ev To Free Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Editas Medicine's Free Cash Flow Yield and Ev To Free Cash Flow is -0.55. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Ev To Free Cash Flow in the same time period over historical financial statements of Editas Medicine, assuming nothing else is changed. The correlation between historical values of Editas Medicine's Free Cash Flow Yield and Ev To Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Editas Medicine are associated (or correlated) with its Ev To Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Free Cash Flow has no effect on the direction of Free Cash Flow Yield i.e., Editas Medicine's Free Cash Flow Yield and Ev To Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.55

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Free Cash Flow

A valuation metric comparing the company's enterprise value to its free cash flow, used to evaluate whether a company is undervalued or overvalued.

Most indicators from Editas Medicine's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Editas Medicine current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.Enterprise Value is likely to gain to about 921.9 M in 2025, whereas Selling General Administrative is likely to drop slightly above 57.9 M in 2025.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	245.7M	247.3M	284.4M	168.4M
Cost Of Revenue	6.3M	177.7M	204.3M	214.5M

Total Operating Expenses Cost Of Revenue

Editas Medicine fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Net Tangible Assets	Current Deferred Revenue	Long Term Debt
Total Assets		0.11	0.64	0.94	0.96	0.79	0.92	-0.78	-0.86	0.87	0.83	0.84	0.71	0.84	0.98	0.94	0.57	0.79	0.86	0.75	0.85	0.98	0.58	0.96	0.62	0.85
Short Long Term Debt Total	0.11		0.03	0.02	-0.12	0.11	0.04	0.19	-0.03	0.05	0.41	-0.01	0.12	0.15	0.13	0.25	0.75	-0.07	-0.02	0.61	0.03	0.16	0.07	-0.11	-0.04	0.52
Other Current Liab	0.64	0.03		0.74	0.6	0.51	0.59	-0.32	-0.86	0.71	0.42	0.79	0.78	0.75	0.54	0.73	0.38	0.49	0.87	0.53	0.79	0.59	0.2	0.61	0.21	0.5
Total Current Liabilities	0.94	0.02	0.74		0.9	0.76	0.94	-0.76	-0.89	0.96	0.77	0.84	0.7	0.78	0.87	0.94	0.5	0.71	0.88	0.71	0.89	0.91	0.58	0.91	0.64	0.82
Total Stockholder Equity	0.96	-0.12	0.6	0.9		0.65	0.89	-0.78	-0.86	0.84	0.69	0.88	0.72	0.85	0.93	0.88	0.31	0.82	0.87	0.53	0.84	0.91	0.47	1.0	0.55	0.7
Other Liab	0.79	0.11	0.51	0.76	0.65		0.72	-0.77	-0.54	0.63	0.78	0.45	0.35	0.41	0.81	0.66	0.73	0.52	0.55	0.83	0.57	0.87	0.77	0.65	0.74	0.73
Property Plant And Equipment Net	0.92	0.04	0.59	0.94	0.89	0.72		-0.8	-0.84	0.94	0.8	0.79	0.67	0.74	0.87	0.9	0.47	0.59	0.83	0.67	0.91	0.9	0.71	0.89	0.69	0.85
Net Debt	-0.78	0.19	-0.32	-0.76	-0.78	-0.77	-0.8		0.54	-0.64	-0.81	-0.52	-0.31	-0.46	-0.81	-0.61	-0.35	-0.53	-0.57	-0.52	-0.63	-0.82	-0.81	-0.78	-0.87	-0.65
Retained Earnings	-0.86	-0.03	-0.86	-0.89	-0.86	-0.54	-0.84	0.54		-0.9	-0.6	-0.95	-0.89	-0.93	-0.77	-0.91	-0.36	-0.66	-0.98	-0.57	-0.95	-0.79	-0.33	-0.87	-0.36	-0.68
Accounts Payable	0.87	0.05	0.71	0.96	0.84	0.63	0.94	-0.64	-0.9		0.67	0.83	0.74	0.78	0.78	0.94	0.43	0.61	0.87	0.65	0.91	0.82	0.51	0.85	0.53	0.78
Cash	0.83	0.41	0.42	0.77	0.69	0.78	0.8	-0.81	-0.6	0.67		0.56	0.45	0.6	0.85	0.77	0.77	0.49	0.6	0.86	0.67	0.88	0.77	0.7	0.77	0.93
Non Current Assets Total	0.84	-0.01	0.79	0.84	0.88	0.45	0.79	-0.52	-0.95	0.83	0.56		0.91	0.98	0.78	0.87	0.27	0.77	0.97	0.48	0.92	0.76	0.26	0.89	0.38	0.64
Non Currrent Assets Other	0.71	0.12	0.78	0.7	0.72	0.35	0.67	-0.31	-0.89	0.74	0.45	0.91		0.91	0.62	0.81	0.3	0.56	0.92	0.46	0.87	0.64	0.23	0.73	0.22	0.61
Other Assets	0.84	0.15	0.75	0.78	0.85	0.41	0.74	-0.46	-0.93	0.78	0.6	0.98	0.91		0.79	0.87	0.36	0.75	0.94	0.53	0.88	0.76	0.21	0.86	0.3	0.68
Cash And Short Term Investments	0.98	0.13	0.54	0.87	0.93	0.81	0.87	-0.81	-0.77	0.78	0.85	0.78	0.62	0.79		0.87	0.6	0.8	0.79	0.75	0.77	0.98	0.6	0.93	0.65	0.83
Common Stock Shares Outstanding	0.94	0.25	0.73	0.94	0.88	0.66	0.9	-0.61	-0.91	0.94	0.77	0.87	0.81	0.87	0.87		0.58	0.68	0.89	0.76	0.89	0.9	0.48	0.89	0.47	0.87
Non Current Liabilities Total	0.57	0.75	0.38	0.5	0.31	0.73	0.47	-0.35	-0.36	0.43	0.77	0.27	0.3	0.36	0.6	0.58		0.28	0.34	0.96	0.37	0.66	0.54	0.33	0.45	0.8
Other Current Assets	0.79	-0.07	0.49	0.71	0.82	0.52	0.59	-0.53	-0.66	0.61	0.49	0.77	0.56	0.75	0.8	0.68	0.28		0.67	0.44	0.55	0.73	0.14	0.82	0.45	0.51
Other Stockholder Equity	0.86	-0.02	0.87	0.88	0.87	0.55	0.83	-0.57	-0.98	0.87	0.6	0.97	0.92	0.94	0.79	0.89	0.34	0.67		0.55	0.96	0.79	0.37	0.88	0.41	0.67
Total Liab	0.75	0.61	0.53	0.71	0.53	0.83	0.67	-0.52	-0.57	0.65	0.86	0.48	0.46	0.53	0.75	0.76	0.96	0.44	0.55		0.58	0.81	0.62	0.54	0.56	0.9
Property Plant And Equipment Gross	0.85	0.03	0.79	0.89	0.84	0.57	0.91	-0.63	-0.95	0.91	0.67	0.92	0.87	0.88	0.77	0.89	0.37	0.55	0.96	0.58		0.8	0.52	0.85	0.5	0.75
Total Current Assets	0.98	0.16	0.59	0.91	0.91	0.87	0.9	-0.82	-0.79	0.82	0.88	0.76	0.64	0.76	0.98	0.9	0.66	0.73	0.79	0.81	0.8		0.67	0.91	0.68	0.87
Property Plant Equipment	0.58	0.07	0.2	0.58	0.47	0.77	0.71	-0.81	-0.33	0.51	0.77	0.26	0.23	0.21	0.6	0.48	0.54	0.14	0.37	0.62	0.52	0.67		0.48	0.86	0.71
Net Tangible Assets	0.96	-0.11	0.61	0.91	1.0	0.65	0.89	-0.78	-0.87	0.85	0.7	0.89	0.73	0.86	0.93	0.89	0.33	0.82	0.88	0.54	0.85	0.91	0.48		0.56	0.71
Current Deferred Revenue	0.62	-0.04	0.21	0.64	0.55	0.74	0.69	-0.87	-0.36	0.53	0.77	0.38	0.22	0.3	0.65	0.47	0.45	0.45	0.41	0.56	0.5	0.68	0.86	0.56		0.66
Long Term Debt	0.85	0.52	0.5	0.82	0.7	0.73	0.85	-0.65	-0.68	0.78	0.93	0.64	0.61	0.68	0.83	0.87	0.8	0.51	0.67	0.9	0.75	0.87	0.71	0.71	0.66

Click cells to compare fundamentals

Editas Medicine Account Relationship Matchups

Editas Medicine fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	572.6M	677.5M	514.3M	499.2M	574.0M	395.9M
Short Long Term Debt Total	26.1M	26.4M	43.9M	36.5M	32.9M	36.1M
Other Current Liab	17.2M	9.9M	20.2M	34.6M	39.7M	41.7M
Total Current Liabilities	58.2M	46.9M	60.1M	63.2M	72.7M	40.9M
Total Stockholder Equity	393.6M	553.6M	360.7M	349.1M	401.5M	239.8M
Other Liab	163.2M	101.5M	60.9M	60.7M	69.8M	71.4M
Property Plant And Equipment Net	39.1M	43.3M	59.2M	45.7M	52.6M	35.0M
Net Debt	(113.5M)	(177.1M)	(97.6M)	(87.1M)	(78.4M)	(82.3M)
Retained Earnings	(665.2M)	(857.7M)	(1.1B)	(1.2B)	(1.1B)	(1.1B)
Accounts Payable	6.4M	5.1M	9.5M	8.3M	9.5M	5.3M
Cash	139.7M	203.5M	141.5M	123.7M	142.2M	146.9M
Non Current Assets Total	153.5M	170.2M	157.6M	158.3M	182.1M	191.2M
Non Currrent Assets Other	4.7M	6.8M	5.3M	8.6M	9.9M	10.4M
Other Assets	1.7M	4.7M	6.8M	5.3M	6.0M	6.3M
Cash And Short Term Investments	511.8M	619.9M	437.4M	323.1M	371.6M	338.9M
Common Stock Shares Outstanding	58.6M	67.6M	68.7M	76.0M	87.4M	49.3M
Liabilities And Stockholders Equity	572.6M	677.5M	514.3M	499.2M	574.0M	395.9M
Non Current Liabilities Total	120.8M	77.0M	93.5M	86.8M	99.9M	115.2M
Other Current Assets	21.9M	14.4M	7.3M	7.5M	8.7M	6.1M
Other Stockholder Equity	1.1B	1.4B	1.4B	1.6B	1.8B	1.9B
Total Liab	179.0M	123.8M	153.6M	150.1M	172.6M	156.1M
Property Plant And Equipment Gross	39.1M	58.8M	80.7M	72.0M	82.8M	86.9M
Total Current Assets	419.1M	507.3M	356.8M	340.8M	392.0M	314.0M
Accumulated Other Comprehensive Income	(46K)	(493K)	(3.6M)	198K	227.7K	239.1K
Property Plant Equipment	39.6M	14.0M	17.1M	15.6M	17.9M	23.1M
Net Tangible Assets	262.4M	393.6M	553.6M	360.7M	414.8M	250.7M
Current Deferred Revenue	23.5M	20.9M	11.3M	8.2M	9.5M	14.2M
Net Receivables	6.0M	267K	5.1M	10.2M	11.7M	12.3M
Short Term Debt	13.6M	20.6M	22.2M	24.3M	28.0M	29.4M
Short Term Investments	262.4M	296.3M	202.8M	199.5M	229.4M	195.2M
Capital Surpluse	811.5M	1.1B	1.4B	1.4B	1.7B	854.8M
Retained Earnings Total Equity	(549.2M)	(665.2M)	(857.7M)	(1.1B)	(970.3M)	(921.8M)
Capital Lease Obligations	26.1M	26.4M	43.9M	36.5M	42.0M	36.2M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Editas Stock Analysis

When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC